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Vasoactive intestinal polypeptide (VIP) is a potent vasodilator and has been successfully used to alleviate hypertension. Consistently,
disruption of VIP gene in mice leads to hypertension. However, its downstream targets in the vascular regulation are still not well demonstrated.
To test the hypothesis that the vascular smooth muscle isoform of KATP channels is a downstream target of the VIP signaling, we performed the
studies on the Kir6.1/SUR2B channel expressed in HEK293 cells. We found that the channel was strongly activated by VIP. Through endogenous
VIP receptors, the channel activation was reversible and dependent on VIP concentrations with the midpoint-activation concentration ∼10 nM.
The channel activation was voltage-independent and could be blocked by KATP channel blocker glibenclamide. In cell-attached patches, VIP
augmented the channel open-state probability with modest suppression of the single channel conductance. The VIP-induced Kir6.1/SUR2B
channel activation was blocked by PKA inhibitor RP-cAMP. Forskolin, an adenylyl cyclase activator, activated the channel similarly as VIP. The
effect of VIP was further evident in the native tissues. In acutely dissociated mesenteric vascular smooth myocytes, VIP activated the KATP
currents in a similar manner as in HEK293 cells. In endothelium-free mesenteric artery rings, VIP produced concentration-dependent vasore-
laxation that was attenuated by glibenclamide. These results therefore indicate that the vascular isoform (Kir6.1/SUR2B) of KATP channels is a
target of VIP. The channel activation relies on the PKA pathway and produces mesenteric arterial relaxation.
© 2007 Elsevier B.V. All rights reserved.Keywords: VIP; K+ channel; Kir6.1; Antagonist; Second messenger; Vascular tone1. Introduction
Vasoactive intestinal polypeptide (VIP) is a 28-amnio-acid
peptide hormone and neurotransmitter present in multiple organs
and systems. VIP has broad effects on cellular functions includ-
ing vasodilation, water reabsorption, neurotransmission, insulin
secretion and immunomodulation [1–3]. These biological effects
are mediated by specific VIP receptors (VPAC1 and VPAC2),
both of which are coupled to G proteins, primarily the GS pro-
teins [4].
As a potent vasodilator, VIP containing nerve terminals
innervate a variety of blood vessels in systemic and pulmonary⁎ Corresponding author. Tel.: +1 404 651 0913; fax: +1 404 651 2509.
E-mail address: cjiang@gsu.edu (C. Jiang).
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doi:10.1016/j.bbamem.2007.08.030circulations [5]. VIP released from the nerve terminals produces
vascular smooth muscle relaxation. Such a vasodilation effect is
50–100 times more potent than acetylcholine [5]. Administra-
tion of VIP to patients with severe cardiovascular diseases such
as primary pulmonary hypertension results in substantial im-
provement in their conditions without adverse side effects [6].
Moderate pulmonary arterial hypertension has been observed in
mice lacking the VIP gene [7,8]. By taking advantage of the
vasodilation effects, several species of animals have developed
VIP-like peptides that are lethal vasodilatory toxins serving for
defense and predatory purposes [9–11].
The downstream molecules of VIP in the vasodilation effect
are still not fully understood [5]. In the vascular smooth muscle
cells, the influx of Ca++ through voltage-dependent Ca++ chan-
nels contributes to vessel constriction, while the preclusion of
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closure of these Ca++ channels are largely controlled by mem-
brane potentials. Activation of the vascular KATP channels
hyperpolarizes the vascular smooth muscle cells, prevents the
Ca++ influx, and relaxes blood vessels. Therefore, the vascular
KATP channels play an important role in vascular tone regulation
[14].
Functional KATP channels are made of four pore-forming
subunits Kir6.x (Kir6.1 or Kir6.2) and four regulatory subunits
sulfonylurea receptor SURx (SUR1, SUR2A or SUR2B) [15].
The former belongs to the inwardly rectifying K+ channels, and
the latter is a member of the ATP-binding cassette (ABC)
protein family [16–18]. A combination of different Kir6.x and
SURx results in distinct KATP channels, such as the Kir6.2/
SUR1 channel in pancreatic β-cells and the Kir6.2/SUR2A
channel in cardiac muscles [19]. The Kir6.1/SUR2B channel is
the major isoform of KATP channels in vascular smooth muscles,
although there is evidence that the Kir6.2 also form functional
channels with SUR2B in blood vessels [20–22]. The biophy-
sical and pharmacological properties of the Kir6.1/SUR2B
channel are comparable to those of KNDP channels found in
native coronary and mesenteric arteries [23,24]. Consistently,
disruptions of the Kcnj8 (Kir6.1) or ABCC9 (SUR2) genes in
mice cause abnormalities in coronary circulation, sudden car-
diac death and fatal susceptibility to endotoxemia [25–27].
Previous studies have suggested that the vascular KATP
channels are subjected to phosphorylation regulation by protein
kinases A, C and G (PKA, PKC, PKG), allowing them to
respond to several vasoactive hormones and neurotransmitters
[28–32]. Since the PKA signaling system can be activated by
VIP, it is possible that the vascular smoothmuscle KATP channels
play a role in vasodilation effect of VIP. To test the hypothesis,
we performed these studies on the Kir6.1/SUR2B channel ex-
pressed in HEK293 cells, cell-endogenous KATP channels from
dissociated smooth myocytes and isolated mesenteric arterial
rings.
2. Methods and materials
2.1. Expression Kir6.1/SUR2B channel in HEK293 cells
Human embryonic kidney cells (HEK293) were used for the expression of
Kir6.1/SUR2B channel. The HEK293 cells were cultured in DMEM/F12 me-
dium with 10% fetal bovine serum and penicillin/streptomycin at 37 °C with 5%
CO2. A eukaryotic expression vector pcDNA3.1 containing Rat Kir6.1 (Gen-
Bank No. D42145) or SUR2B cDNAs (GenBank No. D86038, mRNA isoform
NM_011511) was co-transfected to the cells. A 35-mm petri dish of cells was
transfected with 1 μg Kir6.1 and 3 μg SUR2B using Lipofectamine2000 (Invitro-
gen Inc., Carlsbad, CA). To facilitate the identification of positively transfected
cells, 0.5 μg green fluorescent protein (GFP) cDNA (pEGFP-N2, Clontech, Palo
Alto, CA) was included in the cDNA mixture. 24 h after transfection, cells were
disassociated with 0.25% trypsin, split and transferred to cover slips. Experi-
ments were performed on the cells in the following 6–48 h.
2.2. Electrophysiology
Patch clamp experiments were carried out at room temperature as described
previously [31–33]. In brief, fire-polished patch pipettes with 2–5 MΩ resis-
tance were made from 1.2-mm borosilicate glass capillaries. Whole-cell currents
were recorded in single-cell voltage clamp using the Axopatch 200B amplifier(Axon Instruments Inc., Foster City, CA), low-pass filtered (2 kHz, Bessel 4-
pole filter, −3 dB), and digitized (10 kHz, 16-bit resolution) with Clampex 9
(Axon Instruments Inc.). Data were analyzed using Clampfit 9 (Axon Instru-
ments Inc.). The bath solution contained (in mM): KCL 10, potassium gluconate
135, EGTA 5, glucose 5, and HEPES 10 (pH=7.4). The pipette was filled with a
solution containing: KCl 10, potassium gluconate 133, EGTA 5, glucose 5,
K2ATP 1, NaADP 0.5, MgCl21, and HEPES 10 (pH=7.4). To avoid nucleotide
degradation, all intracellular solutions were freshly made and used within 4 h.
All reagents and chemicals were purchased from Sigma unless otherwise
stated. Pinacidil and glibenclamide were prepared as stock solution of 10 mM in
DMSO. VIP was prepared in 1% acetic acid (v/v). All solvents were tested and
showed no detectable effect on the KATP channels.
2.3. Mesenteric artery preparation and tension measurement
All animal experiments were performed in compliance with an approved
protocol by the Institutional Animal Care and Use Committees (IACUC) at
Georgia State University. Male Sprague–Dawley rats (200–250 g body weight)
were deeply anesthetized followed by decapitation. Mesenteric arteries were
dissected free and placed in PSS containing (in mM): NaCl 140, KCl 4.6, CaCl2
1.5 MgCl2 1, glucose 10, HEPES 5, pH 7.3. The arteries were cut into small
rings (2 mm in length) and transferred to ice-cold Krebs solution containing:
NaCl 118.0, NaHCO3 25.0, KCl 3.6, MgSO4 1.2, KH2PO4 1.2, glucose 11.0,
CaCl2 2.5. The endothelium-free rings were prepared by rubbing with a sanded
polyethylene tubing, and confirmed with vasodilation response to acetylcholine
(ACh) as described previously [31].The arterial ring was mounted on a force
electricity transducer (Model FT-302, iWorx/CBSciences, Inc. Dover, NH) for
measurements of isometric force contraction in a 5-ml tissue bath filled with the
air bubbled Krebs solution. All rings were pre-tested with phenylephrine (PE) to
ensure the tissue vitality. When endothelium needed to be removed, the rings
were tested by PE for contraction followed by an exposure to ACh (1 μM). The
rings were considered to be endothelium-free if more than 90% relaxation was
eliminated. PE and ACh then were washed out, and the rings were allowed to
equilibrate in the Krebs solution for another 30–60 min before experiments.
2.4. Acute dissociation of mesenteric vascular smooth cells
Single vascular smooth cells were preparedwith two-step enzyme digestions.
Main branch of mesenteric arteries was obtained as mentioned above. After
clearance of connective tissue, 1–2 mm small segments were cut and placed in
5 ml solution containing (in mM): NaCl 140, KCl 5.4, MgCl2 1, CaCl2 0.1,
HEPES 10 and D-glucose 10 for 10 min in room temperature. The tissues were
then placed in 1 ml of the same solution with 20U of papain (Worthington, New
Jersey), 1.25 mg dithiothreitol (DTT) and 1% fetal bovine serum. After 25-min
digestion at 35 °C, the tissues were washed and incubated with 440U collagenase
(CLS II, Worthington), 1.25 mg trypsin inhibitor (Sigma) and 1% fetal bovine
serum for 10 min. After thorough washes, the tissues were triturated with a fire-
polished Pasteur pipette to yield single cells. The dissociated smoothmuscle cells
were placed in a petri dish and allowed to attach to the dish surface before
recordings. Patch clamp experiments were carried out in the cells that showed
clear smooth muscle morphology and had no sign of swelling and shrinkage.
2.5. Data analysis
Data were presented as means±S.E. (standard error). Differences were eval-
uated using Student's t-tests or ANOVA, and statistical significancewas accepted
if Pb0.05.3. Result
3.1. Activation of the Kir6.1/SUR2B channel by VIP in HEK293
cells
The Kir6.1/SUR2B channel was transiently expressed in the
HEK293 cells, and whole cell voltage-clamp was performed
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cellular perfusion solution after the formation of whole-cell
configuration. Most cells showed small stable baseline
currents, and the currents in some cells increased slightly
reaching a steady state within a few minutes (Fig. 1A). When
VIP (30 nM) was applied to the cell in the perfusion solution,
the whole-cell currents increased rapidly and reached a plateau
in about 2–3 min. KATP channel opener pinacidil (Pin, 10 μM)
strongly augmented the currents that was subsequently
inhibited by glibenclamide (Glib, 10 μM), a specific KATP
channel inhibitor (Fig. 1A). Thus we used 10 μM Pin and
10 μM Glib throughout the study unless otherwise stated.
Another KATP channel opener, diazoxide (100 μM), opened the
channel to the similar degree as Pin, and its effect was also
totally blocked by Glib (Online Fig. 1). The effect of VIP was
completely blocked in the presence of 10 μM Glib suggesting
that Kir6.1/SUR2B channel is targeted by VIP (Fig. 1B). For
quantitative analysis, the effect of VIP was normalized
between the baseline current and the current activated by
10 μM Pin. Under such a condition, the currents activated by
30 nM VIP averaged 58.0±3.4% (n=5).
Several control experiments were done. The outward cur-
rents were studied together with the inward currents using
depolarizing (−80 mV) and hyperpolarizing (80 mV) com-
mand pulses. The outward currents were affected by VIP and
other K+ channel blockers in a similar proportion as the inward
currents (Online Figs. 1 and 2). Both the Pin-activated inward
and outward currents were insensitive to 30 μM 4-amino-
pyridine (4-AP) and 100 nM charybdotoxin (ChTX), specific
blockers of Kv and BK channels, respectively, but inhibited by
1 mM tetrabutylammonium (TBA) (Online Fig. 2). Finally, theFig. 1. Activation of the Kir6.1/SUR2B channel by VIP in HEK293 cells. (A) Whole-
solutions contained 145 mM K+ so that the reversal potential of K+ currents is close to
of 1 mM ATP, 0.5 mM ADP, and 1 mM free Mg+. Application of VIP (30 nM) incre
channel opener pinacidil (Pin, 10 μM) strongly augmented the currents that was pot
point to where each bottom trace was taken from. (B) The effect of VIP was totallyPin- and Glib-sensitive currents were not observed in cells
transfected with the expression vector alone (Fig. 3B),
indicating that the VIP-elicited current is conducted through
KATP channels.
The activation of the Kir6.1/SUR2B channel by VIP showed
clear concentration-dependence. Evident increase in the current
amplitude was observed with the VIP concentration as low as
1 nM, and stronger activation occurred with higher concentra-
tions (Fig. 2A). The maximum effect (58.0±3.4%) was reached
with 30 nM VIP (Fig. 2B).
Previous studies have shown that the VIP receptor VPAC1 is
constitutively expressed in HEK293 cells [34,35]. We found
that the Kir6.1/SUR2B channel was activated by VIP when
expressed in HEK293 cells without exogenous VIP receptors.
Such a channel activation was significantly diminished by the
VIP receptor antagonist VIP 6–28 (16.1±3.9% 10 nM VIP with
the presence of VIP 6–28 vs. 35.0±7.9% 10 nM VIP without
VIP 6–28; Pb0.05, n=15) (Fig. 2C). When the HEK293 cells
were transfected with the VPAC2 receptor (the VPAC1 receptor
cDNA is not commercially available), VIP (100 nM) did not
show any significant additional effect on the Kir6.1/SUR2B
channel (49.2±4.5% with the VPAC2 receptor vs. 52.8±3.4%
without; PN0.05, n=7). These results suggest that the endo-
genous VIP receptors in the HEK293 cells mediate the VIP
effect, consistent with previous observations on the presence of
endogenous VIP receptors in HEK293 cells [34].
3.2. Biophysical basis for the Kir6.1/SUR2B channel activation
When step voltage protocols were applied, the current acti-
vation by VIP was observed across the whole voltage range fromcell currents were recorded from a cell transfected with Kir6.1/SUR2B. The bath
0 mV. The recording pipette was filled with the same solution with the addition
ased the whole-cell currents rapidly and reached a plateau in about 3 min. KATP
ently inhibited by glibenclamide subsequently (Glib, 10 μM). Note that arrows
blocked in the presence of 10 μM Glib.
Fig. 2. (A–B) The activation of the Kir6.1/SUR2B channel by VIP was concentration-dependent with VIP concentration for a half current activation∼10 nM. (C) The
effect of VIP (10 nM) was significantly diminished in the presence of VIP receptor blocker VIP 6–28 (100 nM).
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activated and Pin-activated currents was normalized to the current
amplitude at −120 mVand plotted in the same X–Y axis system.
Under this condition, the two nearly linear I–V plots super-
imposed with each other nicely, indicating that the current
activation by VIP is voltage-independent (Fig. 3B, C). Such
currents were not seen in cells transfected with the expression
vector alone (Fig. 3D).
To understand the biophysical basis for the Kir6.1/SUR2B
channel activation, single-channel recordings were performed
in cell-attached patches. Exposure to VIP (100 nM) aug-
mented the channel open-state probability (NPo 0.005±0.002Fig. 3. Voltage independence of the Kir6.1/SUR2B channel activation by VIP. (A)
120 mV from a holding potential of 0 mV. The current activation by VIP was observe
was not seen in another cell transfected with the vector alone. (C) The I–V relationshi
nearly linear I–V plots superimposed with each other almost completely indicatingat baseline, 0.048±0.006 with VIP, and 0.116±0.017 with
Pin, n=5) (Fig. 4A). The single-channel conductance was
slightly inhibited by VIP (34.9±0.9 pS before vs. 31.7±1.7
pS after VIP treatment, Pb0.05, n=10; Fig. 4B, C). At
baseline, the closed time was 164.7±74.1 ms (n=6), the level
1 open time was 1.77±0.53 ms (n=6), and the level 2 open
time was 0.73±0.19 ms n=6). During the VIP exposure, the
closed time was reduced to 59.1±7.6 ms (n=7, Pb0.05), while
the level 1 open time (2.28±0.45 ms, n=7) and level 2 open
time (1.06±0.15 ms, n=7) did not change significantly,
indicating that VIP increases the NPo via suppression of the
closed time.Voltage dependence was studied with step command pulses from −120 mV to
d across the whole voltage range in the HEK cell. (B) Similar current activation
p of VIP and Pin was plotted by normalized to the current at −120 mV. The two
the effect of VIP is not voltage-dependent.
Fig. 4. Effect of VIP on single-channel properties. (A) Single-channel currents were recorded in a cell-attached patch. The lower trace in each panel is an expansion
from the record of upper trace between arrows. Two active channels were seen at baseline with rather low channel activity (NPo 0.001). When the cell was exposed to
100 nM VIP, the single-channel activity was augmented (NPo 0.028). The channel activity was further stimulated with 10 μM (NPo 0.152). (B) Single channel
conductance was measured in a cell-attached patch from another cell with a ramp voltage from −100 to 100 mV. An active channel was observed with 100 nM VIP.
The straight line represents a slope conductance of 36 pS. (C) The slope conductance increased modestly, and an additional active channel was recruited in the presence
of pinacidil. The slope conductance is 40 pS for both.
Fig. 5. PKA dependence of the Kir6.1/SUR2B channel activation by VIP. (A) RP-cAMP, a potent PKA inhibitor, was applied in both the pipette solution (200 μM) and
the perfusion solution (100 μM). The VIP-activated Kir6.1/SUR2B currents were greatly attenuated in the presence of RP-cAMP. (B) The Kir6.1/SUR2B channel was
activated by 10 μM forskolin, an adenylyl cyclase activator. (C) After the currents were activated by VIP, forskolin had no additional effect. (D) The forskolin-activated
current had similar characteristics as the VIP-activated current showing no evident voltage-dependence. (E) Summary of VIP effects in the presence or absence of
RP-cAMP and forskolin. The VIP-induced channel activation was significantly reduced in the presence of RP-cAMP (⁎⁎Pb0.01, n=10). Forskolin following VIP did
not produce any significant additional activation in comparison to the effect of VIP alone.
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Previous studies have shown that KATP channels are
regulated by both PKA and PKC [28,29,36,37]. VIP receptors
(VPAC1 and VPAC2) are primarily coupled to GS, stimulation
of which can lead to activation of PKA pathway [4,38]. To
elucidate whether the activation of the Kir6.1/SUR2B channel
by VIP depends on the PKA pathway, 8-(4-chlorophenylthio)
adenosine-3′,5′-cyclic monophosphorothioate Rp-isomer (RP-
cAMP), a PKA inhibitor, was applied in both the pipette solu-
tion (200 μM) and in perfusion solution (100 μM). In the
presence of RP-cAMP, the current activation by 100 nM VIP
was significantly reduced to 11.9±6.9% (Pb0.01, n=10 in
comparison to control) (Fig. 5A, E).
As the adenylyl cyclase is activated by GS, we studied the
Kir6.1/SUR2B currents with forskolin, a potent adenylyl cy-
clase activator. Exposure of the cell to 10 μM forskolin strongly
activated the Kir6.1/SUR2B channel. Such an effect was not
significantly different from the channel activation by 100 nM
VIP (PN0.05, Fig. 5B, E). The forskolin-activated currents also
showed identical characteristics to the current activated by VIP
in their I–V relationship (Fig. 5D in comparison with Fig. 3A).
After the currents were activated by VIP, forskolin had no
additional effect (Fig. 5C, E), further suggesting that the VIP
and forskolin share the same intracellular signaling pathway in
regulating the channel activity.
3.4. Effects of VIP on cell-endogenous KATP channels in
vascular smooth myocytes
The effect of VIP on cell-endogenous KATP channels was
studied on the vascular smooth myocytes (VSM) dissociated
acutely from mesenteric arteries. Under the same recordingFig. 6. Activation of endogenous KATP channels in vascular smooth myocytes. (A) K
augmented with an exposure to 100 nM VIP. The currents were further activated by
with the recording pipette on the right side. (C) The current amplitude increased signicondition as for the HEK293 cells, the inward K+ currents were
recorded from the VSMs. The VSM-endogenous current had
single-channel conductance 34.8±1.1 (n=4) similar to the
Kir6.1/SUR2B current expressed in HEK cells (34.9±0.9,
n=11). The currents were activated with the treatment of 100 nM
VIP, further augmented by Pin (10 μM), and subsequently
inhibited by Glib (10 μM) (Fig. 6), consistent with the Kir6.1/
SUR2B channel activation observed in HEK293 cells.
To further understand whether the regulation of KATP channel
by VIP affects vascular tone, we studied isometric contractions
of endothelium-free mesenteric artery rings. Administration of
phenylephrine (PE) led to a rapid contraction of the arterial
rings which lasted over 30 min without clear desensitization.
The failure of 1 μM carbamylcholine to dilate the ring after
contraction with PE was the evidence of functional endothelial
ablation (Fig. 7A). When VIP was applied, the rings relaxed in
a concentration-dependent manner (Fig. 7B, D). Such a VIP-
induced vasorelaxation was markedly attenuated by a pretreat-
ment with 1 μM Glib (Fig. 7C, D), indicating that the KATP
channels activation plays an important role in the VIP-induced
relaxation.
4. Discussion
Our studies have shown that the Kir6.1/SUR2B channel is a
downstream target of VIP. The channel is strongly activated by
VIP with the midpoint concentration ∼10 nM. The channel
activation is likely mediated through the VIP receptor, adenylyl
cylcase and PKA signaling system. Such KATP channel
activation tends to hyperpolarize the cell and relaxes the
vascular smooth muscle, which is consistent with our data
showing that VIP produces KATP channel relaxation of the
mesenteric arteries.+ currents were recorded in the same condition as in Fig. 1. The currents were
Pin and inhibited by Glib. (B) An acutely dissociated vascular smooth myocyte
ficantly with VIP exposure. Data are presented as mean±S.E. (n=4). ⁎⁎P=0.01.
Fig. 7. Involvement of KATP channel in the VIP-induced vasorelaxation. (A) The
effect of VIP was studied in an endothelium-free mesenteric arterial ring in vitro.
Administration of 1 μM phenylephrine (PE) led to a strong and persistent
contraction of the arterial ring. A subsequent exposure to 1 μM carbamylcholine
relaxed the ring only slightly. (B) The application of VIP in the presence of PE
dilated the artery rings in a concentration-dependent manner. (C) Such
vasorelaxation effect was markedly attenuated by a 30-min pretreatment with
1 μM glibenclamide (Glib). (D) Summary of the vasodilation effect of VIP on
PE-induced vasoconstriction in the presence or the absence of Glib. Data are
presented as mean±S.E. (n=7). ⁎Pb0.05; ⁎⁎⁎Pb0.001.
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suggested for the vasodilation effect of VIP. In the isolated
perfused rat heart, selective activation of VIP receptors pro-
duces vasodilation of the coronary circulation. Such a
vasodilation effect can be blocked by glibenclamide but not
4-aminopyridine, suggesting that KATP channels are involved
[39,40]. Another studies suggest that the vasodilation effect of
VIP is mediated through glibenclamide-insensitive channels
[41,42]. Clearly, VIP may affect vascular tones via multiple
mechanisms that remain to be understood, as these previousstudies rely on sulfonylureas that are known to affect other ion
channels as well [43,44]. Using the cloned channel in the HEK
expression system, we have revealed that Kir6.1/SUR2B
channel is one of the downstream molecules. In the mesenteric
VSMs, activation of Maxi-K channels also contributes to the
vasorelaxation response to VIP, in which the cAMP-dependent
signaling pathways seem to be involved [45]. In the
gastrointestinal system, VIP can produce relaxation of the
sphincter of Oddi which can be attenuated by glibenclamide
[46]. Consistent with these previous studies, our results show
that VIP relaxes isolated mesenteric rings, an effect that can be
blocked by glibenclamide. Our studies in a heterologous
expression system have indicated that the cloned Kir6.1/
SUR2B channel indeed is activated by VIP. As the Kir6.1/
SUR2B channel is expressed in vascular smooth muscles
[33,47,48], and as the channel protein may be phosphorylated
by PKA [28,29], it is likely that the activation of the Kir6.1/
SUR2B channel contributes to the vasodilation effect of VIP.
The KATP channels play an important role in membrane
potentials and cell activity [15,17]. These K+ channels are in-
hibited by physiological concentrations of ATP and are open
when ATP level drops during metabolic stress. Such a property
allows them to regulate several cellular functions during meta-
bolic stress, including vascular tone regulation, myocardium
excitability control, neuronal responses to hypoxic ischemia,
insulin secretion in pancreatic β-cells, and glucose uptake in
striated muscles [15,17,19]. The Kir6.1/SUR2B channel is likely
to be the major isoform of KATP channels in vascular smooth
muscles, whose pharmacological properties resemble those of
the native KNDP channels in vascular smooth myocytes [49–51].
The involvement of Kir6.1/SUR2B in vascular tone regulation
has been demonstrated in both physiological and pathological
conditions. Activation of these KATP channels in response to
local regulators hyperpolarizes vascular smooth muscles and
dilates resistance arteries leading to redistribution of the blood
flow [15], while the disruption of the Kcnj8 (Kir6.1) or ABCC9
(SUR2) genes in mice causes abnormalities in coronary circu-
lation, sudden cardiac death and fatal susceptibility to endo-
toxemia [25–27]. The vascular KATP channel is regulated by a
variety of vasoactive substances especially circulating hor-
mones and neurotransmitters. Several studies have suggested
that the regulation of the vascular KATP channel is achieved
via phosphorylation of the channel proteins by protein kinases
that are activated through specific intracellular singling
pathways [52,53]. Therefore, the understanding of the KATP
channel function in vascular tone control depends on the
demonstration of the precise signal pathway underlying the
channel modulation.
Several other intracellular signaling pathways may be in-
volved in the vasodilation effect of VIP. The VIP effect has been
shown to rely on the VPAC2 receptor in the coronary circulation
[39]. Because of the lack of specific receptor blockers, we could
not differentiate VPAC1 from VPAC2 in our studies. According
to previous studies, the VPAC1 is expressed in the HEK293
cells [34,35], suggesting that the Kir6.1/SUR2B channel acti-
vation may be produced by VPAC1. However, we cannot rule
out the involvement of VPAC2 as both VPAC1 and VPAC2
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cyclase and PKA.
Although the VIP receptor–adenylyl cylcase –PKA system
seems critical, VIP also can activate PKG pathway [54−56]. In
addition, the VIP-induced relaxation of aorta and uterine ar-
teries has been shown to be produced by nitric oxide (NO)
released from the endothelial cells [56,57]. Another study how-
ever suggests that NO synthesis is not affected by VIP, while
stimulation of endogenous NO production provokes VIP release
from nerve terminals [54]. Since endothelium-free arterial rings
were used, our results from the present study suggest that the
effect of VIP on vasorelaxation is NO-independent. Because
of the presence of these diverse signaling molecules, distinct
intracellular signaling pathways appear to play a role in the VIP
signaling targeting at perhaps different effector molecules.
Thus, the demonstration of the adenylyl cyclase–PKA–Kir6.1/
SUR2B pathway in the present study is of significance in
understanding the vascular effect of VIP.
In conclusion, our results indicate that the Kir6.1/SUR2B
channel is a downstream target of VIP signaling. The activation
of the major vascular isoform of KATP channels can produce
hyperpolarization and relaxation of vascular smooth muscles,
which is consistent with the effect of VIP on mesenteric arteries.
The information that we have found for the VIP signaling
pathway may be useful for the manipulation of specific mem-
brane and intracellular signal molecules in the control of vas-
cular tones.
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